TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt
Brief Summary: To validate the dosing algorithm for dabigatran etexilate in patients receiving a mechanical heart valve.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2
B: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD0837 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD0837 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD0837 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: AZD0837 | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin-K antagonist at INR 2-3 | Intervention Type: DRUG; Name: AZD0837; Assigned to Arm(s): 1, 3, 4 | Intervention Type: DRUG; Name: Vitamin-K antagonist at INR 2-3; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: AZD0837; Assigned to Arm(s): 2
D: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 1mg, Drug: warfarin 5mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt
Brief Summary: To validate the dosing algorithm for dabigatran etexilate in patients receiving a mechanical heart valve.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 1mg, Drug: warfarin 5mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin
D: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 5mg, Drug: warfarin 1mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt
Brief Summary: To validate the dosing algorithm for dabigatran etexilate in patients receiving a mechanical heart valve.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Patient Self Testing; Type: ACTIVE_COMPARATOR; Interventions: Device: INRatio monitor by Hemosense | Intervention Type: DEVICE; Name: INRatio monitor by Hemosense; Assigned to Arm(s): Patient Self Testing | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 5mg, Drug: warfarin 1mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Warfarin | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Group B
D: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 1mg, Drug: warfarin 5mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome
Brief Summary: The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after utero exposure to opioids. In an open label Phase 1 trial sublingual buprenorphine was associated with a \~30% reduction length of treatment compared to standard of care morphine. Due to the subjective nature of the scoring instrument, efficacy in a blinded trial is needed to unequivocally establish the superiority of buprenorphine over morphine. The primary objective of the trial is to compare length of treatment using sublingual buprenorphine or oral morphine solution in the pharmacologic treatment of the NAS.


Options:
A: Arm Label: 1 (Phenobarbital and Methadone); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: 2 (Phenobarbital and Diluted Deodorized Tincture of Opium); Type: ACTIVE_COMPARATOR; Interventions: Drug: Diluted Deodorized Tincture of Opium | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): 1 (Phenobarbital and Methadone) | Intervention Type: DRUG; Name: Diluted Deodorized Tincture of Opium; Assigned to Arm(s): 2 (Phenobarbital and Diluted Deodorized Tincture of Opium)
B: Arm Label: sublingual buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: sublingual buprenorphine | Arm Label: oral morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral morphine | Intervention Type: DRUG; Name: sublingual buprenorphine; Assigned to Arm(s): sublingual buprenorphine | Intervention Type: DRUG; Name: oral morphine; Assigned to Arm(s): oral morphine
C: Arm Label: Song of Kin; Type: EXPERIMENTAL; Interventions: Behavioral: Song of Kin | Arm Label: Gato box; Type: EXPERIMENTAL; Interventions: Other: Gato box | Arm Label: Ocean disc; Type: EXPERIMENTAL; Interventions: Other: Ocean disc | Arm Label: Contingent singing; Type: EXPERIMENTAL; Interventions: Other: Contingent singing | Arm Label: Tonal Vocal holding; Type: EXPERIMENTAL; Interventions: Other: Tonal Vocal holding | Arm Label: Muted shaker; Type: EXPERIMENTAL; Interventions: Other: Muted shaker | Intervention Type: BEHAVIORAL; Name: Song of Kin; Assigned to Arm(s): Song of Kin | Intervention Type: OTHER; Name: Gato box; Assigned to Arm(s): Gato box | Intervention Type: OTHER; Name: Ocean disc; Assigned to Arm(s): Ocean disc | Intervention Type: OTHER; Name: Contingent singing; Assigned to Arm(s): Contingent singing | Intervention Type: OTHER; Name: Tonal Vocal holding; Assigned to Arm(s): Tonal Vocal holding | Intervention Type: OTHER; Name: Muted shaker; Assigned to Arm(s): Muted shaker
D: Arm Label: Low lactose formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Arm Label: Regular formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Intervention Type: OTHER; Name: Low lactose or regular formula; Assigned to Arm(s): Low lactose formula, Regular formula

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome
Brief Summary: The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after utero exposure to opioids. In an open label Phase 1 trial sublingual buprenorphine was associated with a \~30% reduction length of treatment compared to standard of care morphine. Due to the subjective nature of the scoring instrument, efficacy in a blinded trial is needed to unequivocally establish the superiority of buprenorphine over morphine. The primary objective of the trial is to compare length of treatment using sublingual buprenorphine or oral morphine solution in the pharmacologic treatment of the NAS.


Options:
A: Arm Label: SVS vs Control; Type: EXPERIMENTAL; Interventions: Device: Stochastic Vibrotactile Stimulation (SVS), Other: Control | Intervention Type: DEVICE; Name: Stochastic Vibrotactile Stimulation (SVS); Assigned to Arm(s): SVS vs Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): SVS vs Control
B: Arm Label: Low lactose formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Arm Label: Regular formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Intervention Type: OTHER; Name: Low lactose or regular formula; Assigned to Arm(s): Low lactose formula, Regular formula
C: Arm Label: sublingual buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: sublingual buprenorphine | Arm Label: oral morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral morphine | Intervention Type: DRUG; Name: sublingual buprenorphine; Assigned to Arm(s): sublingual buprenorphine | Intervention Type: DRUG; Name: oral morphine; Assigned to Arm(s): oral morphine
D: Arm Label: Oral morphine solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral morphine solution | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine | Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Oral morphine solution; Assigned to Arm(s): Oral morphine solution

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Brazilian Heart Prevent Meal Program Accessible for the Population to Prevent New Cardiovascular Events: A Pilot Randomized Clinical Trial
Brief Summary: The purpose of this study is to evaluate the effectiveness of a brazilian cardioprotective diet plan to reduce cardiovascular risk factors of new cardiovascular events.


Options:
A: Arm Label: Stanol ester; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Stanol ester spread | Arm Label: Placebo spread; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo spread | Arm Label: Mediterranean diet group; Type: OTHER; Interventions: Dietary Supplement: Mediterranean Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Stanol ester spread; Assigned to Arm(s): Stanol ester | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo spread; Assigned to Arm(s): Placebo spread | Intervention Type: DIETARY_SUPPLEMENT; Name: Mediterranean Diet; Assigned to Arm(s): Mediterranean diet group
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Other: Brazilian heart-prevent meal | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Other: Heart prevent control meal weekly | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Other: Heart prevent control Meal monthly | Intervention Type: OTHER; Name: Brazilian heart-prevent meal; Assigned to Arm(s): Group 1 | Intervention Type: OTHER; Name: Heart prevent control meal weekly; Assigned to Arm(s): Group 2 | Intervention Type: OTHER; Name: Heart prevent control Meal monthly; Assigned to Arm(s): Group 3
C: Arm Label: Experimental diet; Type: EXPERIMENTAL; Interventions: Other: Experimental diet | Arm Label: Control diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Control diet | Intervention Type: OTHER; Name: Experimental diet; Assigned to Arm(s): Experimental diet | Intervention Type: OTHER; Name: Control diet; Assigned to Arm(s): Control diet
D: Arm Label: DASH diet; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet | Arm Label: DASH diet plus Weight loss; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet plus Weight loss | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: DASH diet; Assigned to Arm(s): DASH diet | Intervention Type: BEHAVIORAL; Name: DASH diet plus Weight loss; Assigned to Arm(s): DASH diet plus Weight loss

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Brief Summary: The purpose of this study is to determine, relative to placebo, the effect of iron repletion therapy using intravenous (IV) ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.


Options:
A: Arm Label: Ferinject (ferric carboxymaltose); Type: EXPERIMENTAL; Interventions: Drug: Ferinject (ferric carboxymaltose) | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DRUG; Name: Ferinject (ferric carboxymaltose); Assigned to Arm(s): Ferinject (ferric carboxymaltose) | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: Ferinject (ferric carboxymaltose); Type: EXPERIMENTAL; Interventions: Drug: Ferinject (ferric carboxymaltose) | Arm Label: Placebo (saline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (saline) | Intervention Type: DRUG; Name: Ferinject (ferric carboxymaltose); Assigned to Arm(s): Ferinject (ferric carboxymaltose) | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): Placebo (saline)
C: Arm Label: Ferinject; Type: EXPERIMENTAL; Interventions: Drug: Ferinject | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline | Intervention Type: DRUG; Name: Ferinject; Assigned to Arm(s): Ferinject | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Saline
D: Arm Label: Anemia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid | Arm Label: Iron deficiency; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid | Arm Label: Natural comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid; Assigned to Arm(s): Anemia, Iron deficiency

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata
Brief Summary: The use of topical steroids in the treatment of alopecia areata in children is common practice. However, no particular potency of steroid is accepted as the standard treatment due to the paucity of high quality evidence in the dermatology literature to substantiate their use. Two randomized controlled trials exist assessing topical steroid efficacy in this disorder, both have methodological limitations. The question remains as to which topical steroid is safe and efficacious for use. We performed a double blinded controlled trial to assess the usefulness of a class 1 topical steroid (clobestasol proprionate 0.05%) compared with a class 7 topical steroid (hydrocortisone 1%) in children with alopecia areata.


Options:
A: Arm Label: Phototherapeutic; Type: EXPERIMENTAL; Interventions: Radiation: ultraviolet A (UVA) | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone Acetonide | Intervention Type: RADIATION; Name: ultraviolet A (UVA); Assigned to Arm(s): Phototherapeutic | Intervention Type: DRUG; Name: Triamcinolone Acetonide; Assigned to Arm(s): Conventional therapy
B: Arm Label: Baricitinib High Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Baricitinib Low Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-Label Addenda Baricitinib High Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib | Intervention Type: DRUG; Name: Baricitinib; Assigned to Arm(s): Baricitinib High Dose, Baricitinib Low Dose, Open-Label Addenda Baricitinib High Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Baricitinib High Dose, Baricitinib Low Dose, Placebo
C: Arm Label: Dupilumab; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Hydrocortisone 1%; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone 1% | Arm Label: Clobetasol Propionate 0.05%; Type: EXPERIMENTAL; Interventions: Drug: Clobetasol Propionate 0.05% | Intervention Type: DRUG; Name: Hydrocortisone 1%; Assigned to Arm(s): Hydrocortisone 1% | Intervention Type: DRUG; Name: Clobetasol Propionate 0.05%; Assigned to Arm(s): Clobetasol Propionate 0.05%

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A
Brief Summary: The primary objective of the study is to evaluate the long-term safety of recombinant human Factor VIII Fc fusion protein (rFVIIIFc) in participants with hemophilia A. The secondary objective of the study is to evaluate the efficacy of rFVIIIFc in the prevention and treatment of bleeding episodes in participants with hemophilia A.


Options:
A: Arm Label: Concizumab; Type: EXPERIMENTAL; Interventions: Drug: Concizumab, Drug: Eptacog alfa | Arm Label: Eptacog alfa and concizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concizumab, Drug: Eptacog alfa | Intervention Type: DRUG; Name: Concizumab; Assigned to Arm(s): Concizumab, Eptacog alfa and concizumab | Intervention Type: DRUG; Name: Eptacog alfa; Assigned to Arm(s): Concizumab, Eptacog alfa and concizumab
B: Arm Label: On-Demand; Type: EXPERIMENTAL; Interventions: Drug: rFVIIIFc | Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: rFVIIIFc | Intervention Type: DRUG; Name: rFVIIIFc; Assigned to Arm(s): On-Demand, Prophylaxis
C: Arm Label: All participants; Type: EXPERIMENTAL; Interventions: Drug: BIIB031 (rFVIIIFc), Drug: FVIII (PK subgroup only) | Intervention Type: DRUG; Name: BIIB031 (rFVIIIFc); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: FVIII (PK subgroup only); Assigned to Arm(s): All participants
D: Arm Label: Pharmacokinetic (PK) evaluation of BAX 855; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Arm Label: FVIII trough target 1-3%; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Arm Label: FVIII trough target 8-12%; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Pharmacokinetic (PK) evaluation of BAX 855 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): FVIII trough target 1-3% | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): FVIII trough target 8-12%

Answer: B